Key result
Zofenopril linked to reduced CV death or hospitalization in patients with CAD and hypertension.
Why the study?
The high prevalence of coronary heart disease combined with arterial hypertension and their role in fatal complications highlight the need for optimal ACE inhibitors with organ-protective effects.
Does zofenopril reduce cardiovascular events and improve symptoms in patients with coronary heart disease and arterial hypertension?
Does zofenopril reduce cardiovascular events and improve symptoms in patients with coronary heart disease and arterial hypertension?
Zofenopril is an effective and safe ACE inhibitor for patients with coronary heart disease and arterial hypertension, particularly post-MI, reducing cardiovascular events and improving symptoms.
Supports zofenopril consideration for organ protection in CHD with AH; leaves open comparative efficacy versus other ACE inhibitors in prospective trials.
The wide prevalence (82%) of coronary heart disease (CHD) in combination with arterial hypertension (AH), as well as its initiating role in the development of fatal complications, such as myocardial infarction (MI) or heart failure, emphasise the need for the choice of optimal ACE inhibitors with organ-protective characteristics. This paper presents a literature review on the effectiveness of a SH-containing ACE inhibitor zofenopril in patients with CHD and AH, in terms of its anti-anginal and antihypertensive activity. The authors summarise the results of the international SMILE studies which included patients after acute MI. It was demonstrated that zofenopril therapy is associated with reduced combined incidence of cardiovascular death or cardiovascular hospitalisation, and is also safe in the acute post-MI period. In patients with preserved left ventricular function, zofenopril reduced the incidence of angina attacks and arrhythmias of coronary genesis, as well as improved exercise capacity. A clinical case of zofenopril therapy, as a part of a complex treatment regimen, is also presented.
No takes yet. Share an insight, caveat, or question.
Евдокимова et al. (2012) conducted a review in Coronary heart disease and arterial hypertension. Zofenopril was evaluated. Zofenopril therapy in patients with coronary heart disease and arterial hypertension, including post-myocardial infarction, is associated with reduced cardiovascular death or hospitalization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: